Opinion

Video

Overview of Novel Treatments for Retinal Vascular Diseases

A panelist discusses novel treatments for retinal vascular diseases, including faricimab, aflibercept, and port delivery system with ranibizumab.

Video content above is prompted by the following:
Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

  1. Faricimab
  2. Aflibercept 8mg
  3. port delivery system with ranibizumab

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
Related Content
(Image credit: AdobeStock/upnowgraphics) Ophthalmology Times: AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium
June 9th 2025

AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Photo courtesy of Malvina Eydelman, MD)
May 18th 2025

Q&A: Malvina Eydelman, MD, on leading CCOI and catalyzing global ophthalmic innovation

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
May 11th 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
May 10th 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

© 2025 MJH Life Sciences

All rights reserved.